Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020

Rhea-AI Summary

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology firm, is set to report its second quarter 2020 financial results on August 6, 2020, at 7:05 AM ET. The company focuses on developing branded and generic topical drugs for skin diseases, utilizing its proprietary microencapsulation technology. Key products include Twyneo for acne vulgaris and Epsolay for rosacea. The pipeline also features early-stage and preclinical assets targeting various skin conditions.

Positive

• Upcoming Q2 2020 financial results on August 6, 2020.
• Development of innovative products like Twyneo and Epsolay.

Negative

• None.

NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2020 financial results on Thursday, August 6, 2020 at 7:05 AM ET.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com 

Source: Sol-Gel Technologies Ltd.

FAQ

When will Sol-Gel Technologies report its Q2 2020 financial results?

Sol-Gel Technologies will report its Q2 2020 financial results on August 6, 2020, at 7:05 AM ET.

What products are in Sol-Gel Technologies' pipeline?

Sol-Gel's pipeline includes Twyneo for acne vulgaris, Epsolay for rosacea, and SGT-210 for palmoplantar keratoderma, among others.

What is the stock symbol for Sol-Gel Technologies?

The stock symbol for Sol-Gel Technologies is SLGL.